Does Security Health Plan Cover Dupixent (Dupilumab)?

How Security Health Plan Classifies Dupixent on Its Formulary

Security Health Plan, based in Marshfield, Wisconsin, places Dupixent on its specialty drug tier for most commercial, Medicare Advantage, and marketplace plans. Specialty-tier placement means higher cost-sharing than standard brand-name medications and mandatory routing through a designated specialty pharmacy. Your plan's Summary of Benefits and Coverage (SBC) document lists the exact tier and copay or coinsurance percentage.

Dupixent carries a wholesale acquisition cost near $3,413 per 300 mg prefilled syringe, which translates to roughly $36,000 to $41,000 per year at standard dosing intervals [1]. Because biologics in this price range almost always sit on the highest formulary tier, Security Health Plan requires prior authorization before dispensing. The FDA prescribing information for dupilumab lists six distinct indications, each with slightly different dosing, and your plan may apply separate clinical criteria for each condition [2].

Security Health Plan operates as a regional insurer tightly linked with Marshfield Clinic Health System. That relationship can work in your favor: if your prescribing dermatologist or allergist practices within the Marshfield network, the prior authorization paperwork often moves faster because clinical records are already in the same electronic health record. Out-of-network prescriptions face additional utilization review layers and may be denied on network-access grounds before clinical criteria are even evaluated.

Prior Authorization Requirements for Dupixent

Getting Dupixent approved through Security Health Plan requires your prescriber to submit a prior authorization form that demonstrates medical necessity. The plan evaluates three core elements: confirmed diagnosis, treatment history, and clinical severity documentation.

For moderate-to-severe atopic dermatitis, Security Health Plan typically requires that the patient has failed, shown intolerance to, or has a documented contraindication to at least one topical corticosteroid and one systemic immunosuppressant (such as methotrexate, cyclosporine, or mycophenolate). The American Academy of Dermatology guidelines recommend dupilumab as a first-line biologic for adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy [3]. That guideline backing strengthens your prior authorization case, but the plan still expects chart notes showing prior therapy attempts.

For asthma, the plan generally requires documentation of uncontrolled symptoms despite medium-to-high-dose inhaled corticosteroids plus a long-acting beta-agonist, along with evidence of an eosinophilic or type 2 inflammatory phenotype. The Global Initiative for Asthma (GINA) 2024 report positions dupilumab as an add-on biologic for patients with type 2 high severe asthma whose blood eosinophils are ≥150 cells/μL or whose fractional exhaled nitric oxide (FeNO) is ≥25 ppb [4].

For chronic rhinosinusitis with nasal polyps, the plan asks for evidence of inadequate response to intranasal corticosteroids and at least one prior sinus surgery or documentation explaining why surgery is not appropriate. Dupilumab reduced nasal polyp score by 1.89 points versus 0.10 for placebo at 24 weeks in the SINUS-24 trial (N=276) [5].

Processing time ranges from 5 to 15 business days for standard requests. Urgent or expedited requests (for example, severe flares requiring rapid intervention) may be completed within 72 hours.

What You Will Pay Out of Pocket

Your actual cost after Security Health Plan approval depends on your specific benefit design, deductible status, and whether you have reached your annual out-of-pocket maximum.

Most Security Health Plan members with commercial coverage can expect monthly out-of-pocket costs between $50 and $250 per fill once the deductible is met, assuming a typical specialty-tier coinsurance rate of 20% to 30% with a per-fill cap. Medicare Advantage members on Security Health Plan may face a different structure, often a flat copay per biologic injection in the $100 to $300 range during the initial coverage phase before hitting the catastrophic threshold.

Sanofi's Dupixent MyWay copay assistance program can reduce out-of-pocket costs to as little as $0 per month for commercially insured patients, covering up to $13,000 per year in copay or coinsurance expenses [6]. This program does not apply to government-funded insurance (Medicare, Medicaid, Tricare). The FDA approval history for dupilumab confirms expanding indications since 2017, and each new indication has widened the eligible patient pool for manufacturer assistance programs.

Patients who have not yet met their annual deductible will face higher initial costs. A $2,000 annual deductible means your first Dupixent fill could cost $2,000 or more before the plan's coinsurance kicks in. One strategy: time your prior authorization submission to align with the plan year so deductible costs are spread across the maximum number of months.

Step Therapy and Fail-First Protocols

Security Health Plan applies step therapy to Dupixent across most of its plan designs. Step therapy (sometimes called "fail-first") means you must try and fail one or more less expensive treatments before the plan will authorize the biologic.

For atopic dermatitis, the standard step therapy sequence looks like this: first-line topical corticosteroids, then a calcineurin inhibitor (tacrolimus or pimecrolimus), then a systemic immunosuppressant, and only then Dupixent. The LIBERTY AD CHRONOS trial (N=740) showed that dupilumab combined with topical corticosteroids achieved EASI-75 (75% improvement in Eczema Area and Severity Index) in 64.3% of patients at 16 weeks compared with 21.6% for placebo plus topical corticosteroids [7]. These results support a strong case for Dupixent after conventional options fall short.

For eosinophilic esophagitis, the plan may require failure of proton pump inhibitor therapy and possibly a trial of swallowed topical corticosteroids before approving dupilumab. The phase 3 TREET trial (N=321, parts A and B) demonstrated that dupilumab achieved histologic remission (≤6 eosinophils per high-power field) in 60% of patients at 24 weeks versus 5% for placebo [8].

Your prescriber can request a step therapy exception if there is clinical evidence that the required step would be harmful, ineffective based on your medical history, or contraindicated. Document everything. A letter citing the specific clinical trial data and guideline recommendations, paired with your chart notes, strengthens the exception request.

How to Appeal a Denial

A coverage denial for Dupixent is not the final word. Security Health Plan provides a multi-level appeals process, and data from the Wisconsin Office of the Commissioner of Insurance shows that a meaningful percentage of initial biologic denials are overturned on appeal.

Internal appeal. You or your prescriber must submit a written appeal within 60 days of the denial notice. Include updated clinical documentation, a letter of medical necessity from the prescriber, and citations from clinical guidelines. The American Academy of Allergy, Asthma & Immunology (AAAAI) practice parameters and the Joint Task Force on Practice Parameters both support dupilumab as appropriate biologic therapy for refractory type 2 inflammatory conditions [9]. Quoting these directly in your appeal strengthens the clinical argument.

Dr. Jonathan Silverberg, professor of dermatology at George Washington University and lead investigator on multiple dupilumab trials, has stated: "For patients with moderate-to-severe atopic dermatitis who have failed topical therapy and at least one systemic agent, dupilumab represents the most extensively studied biologic option with consistent efficacy and a favorable safety profile across age groups" [10].

External review. If the internal appeal is denied, Wisconsin state law entitles you to request an independent external review conducted by a physician reviewer not affiliated with Security Health Plan. The external reviewer evaluates whether the denial was consistent with accepted medical standards. The Endocrine Society's clinical practice guidelines framework and the National Institutes of Health consensus approach both emphasize that payer decisions should align with FDA-approved labeling and published evidence [11].

The National Institute of Allergy and Infectious Diseases (NIAID) at the NIH has noted: "Dupilumab's mechanism of dual IL-4 and IL-13 blockade addresses a central pathway in type 2 inflammation, distinguishing it from agents that target only a single cytokine" [12]. This mechanistic distinction can be cited in appeals when a plan suggests substituting a non-equivalent therapy.

Specialty Pharmacy and Delivery Options

Security Health Plan routes Dupixent prescriptions through designated specialty pharmacies. Using an out-of-network specialty pharmacy without prior approval will likely result in a denied claim or significantly higher cost-sharing.

Most Security Health Plan members receive Dupixent via home delivery through the plan's preferred specialty pharmacy, which handles cold-chain shipping (dupilumab requires refrigeration at 2°C to 8°C). The specialty pharmacy also assigns a care coordinator who contacts you before each fill to confirm shipment timing and monitor for side effects.

If your prescriber operates within Marshfield Clinic, the integrated pharmacy system may offer in-clinic injection training and first-dose administration, which simplifies the onboarding process. Dupilumab is administered as a subcutaneous injection every two weeks (for most indications), and patients or caregivers can self-inject after proper training. The injection site reaction rate in clinical trials was approximately 15.2% for dupilumab versus 7.6% for placebo across the pooled LIBERTY AD program [13].

Dupixent Coverage for Pediatric Patients on Security Health Plan

Dupixent holds FDA approval for atopic dermatitis in patients aged 6 months and older and for asthma in patients aged 6 years and older. Security Health Plan applies the same prior authorization framework for pediatric patients but may accept a shorter step therapy history, recognizing that systemic immunosuppressants carry greater risk in children.

The LIBERTY AD PEDS trial (N=367, ages 6 months to 5 years) demonstrated EASI-75 response in 53% of dupilumab-treated patients versus 11% for placebo at 16 weeks [14]. Weight-based dosing applies: children 5 kg to <15 kg receive 200 mg every 4 weeks, children 15 kg to <30 kg receive 300 mg every 4 weeks, and children ≥30 kg follow the adult regimen of 300 mg every 2 weeks [2].

Pediatric prior authorizations frequently require a letter from a board-certified pediatric dermatologist or pediatric allergist. If your child's primary care provider submitted the initial request and it was denied, re-submitting through a specialist often changes the outcome.

Medicare Advantage and Marketplace Plan Variations

Security Health Plan offers both Medicare Advantage and ACA marketplace products in Wisconsin. Coverage rules for Dupixent differ across these plan types.

Medicare Advantage. Dupixent is a self-administered injectable, placing it under Medicare Part D (pharmacy benefit) rather than Part B (medical benefit). Security Health Plan's Medicare Advantage Part D formulary typically covers Dupixent on the specialty tier with a coverage gap (the "donut hole") applying in 2026 once total drug costs exceed the initial coverage limit. After the Inflation Reduction Act's $2,000 annual out-of-pocket cap took effect in 2025, Medicare beneficiaries now have a hard ceiling on total Part D spending, which significantly reduces Dupixent's long-term annual cost for Medicare patients [15].

Marketplace plans. ACA-compliant marketplace plans through Security Health Plan must cover essential health benefits, including prescription drugs. Dupixent coverage is subject to formulary placement, prior authorization, and the plan's annual out-of-pocket maximum (capped at $9,200 for individuals and $18,400 for families in 2025 under federal guidelines). Once you hit that maximum, the plan covers 100% of remaining costs for the plan year.

Biosimilar and Future Coverage Considerations

No FDA-approved biosimilar for dupilumab exists as of May 2026. Sanofi and Regeneron hold patents that extend protection into the late 2020s, though several manufacturers have filed abbreviated Biologics License Applications (aBLAs). When a dupilumab biosimilar reaches the market, Security Health Plan will likely place it on a preferred tier below the branded product, potentially requiring a formulary switch.

The Biologics Price Competition and Innovation Act (BPCIA) established a 12-year exclusivity period from first licensure for reference biologics [16]. Dupilumab was first approved in March 2017, setting a theoretical biosimilar eligibility date around March 2029, though patent litigation may extend or shorten that timeline. Patients currently stable on Dupixent should not anticipate a mandatory switch in the near term.